Bon Secours Mercy Health moves into the ASC consolidation race with $5.7 billion Surgery Partners deal
Bon Secours Mercy Health has agreed to acquire Surgery Partners in a take-private transaction valued at about $5.7 billion including debt, a move that pushes one more large nonprofit system into the escalating fight for ambulatory surgical market share. The acquisition, announced Oct. 26, would place more than 200 ambulatory surgery centers, surgical hospitals and physician practices across 30 states under the umbrella of a 47-hospital system already operating at significant scale.
The structure of the deal matters because it signals a strategic shift, not a cautious pilot. Health systems are no longer treating ambulatory surgery as a peripheral extension of inpatient care; they are buying scale, physician alignment and geographic reach in one transaction. For Bon Secours Mercy Health, the purchase offers immediate access to an established outpatient platform instead of years of organic buildout, a timeline that would be difficult to match in a market where payers keep steering appropriate procedures toward lower-cost sites.
Scale, geography and payer pressure are driving the ambulatory shift
The transaction arrives as the economics of surgical care continue to migrate away from the hospital campus. Payers want procedures performed in lower-cost environments whenever clinical complexity allows, and patients increasingly expect faster scheduling, shorter recovery times and easier access. Those forces have turned the ambulatory surgery center into a strategic asset rather than a convenient adjunct.
Ascension and Tenet Healthcare have already shown how aggressively systems are pursuing that model. Ascension’s $3.9 billion acquisition of Amsurg closed earlier this year and expanded its ASC footprint from 58 centers to more than 300. Tenet’s ambulatory arm, United Surgical Partners International, remains the largest ASC portfolio in the country and continues to expand through regular acquisitions. In that context, Bon Secours Mercy Health is not entering a novel market. It is trying to avoid being left behind in one that has already consolidated around a few dominant operators.
A single sentence captures the competitive reality: the systems with the deepest ASC portfolios are now shaping where care gets delivered.
Bon Secours is buying speed, not just facilities
Bon Secours Mercy Health enters the deal with nearly $14 billion in total operating revenue in 2025 and $324 million in recurring operating income, a 2.3% margin. Those numbers suggest a system with enough scale to finance a transformational acquisition but not so much excess margin that it can afford to wait for gradual expansion. The Surgery Partners transaction will be funded with cash on hand and new debt, a combination that reflects confidence in the long-term outpatient revenue opportunity and the strategic necessity of moving now.
Surgery Partners will keep its name, brand and headquarters and remain a secular organization rather than becoming part of Bon Secours Mercy Health’s Catholic ministry. Bain Capital affiliates, which own about 39% of Surgery Partners, will roll their shares into equity in the acquiring entity and remain significant partners in the combined platform. Those details suggest continuity in the operating model, not a wholesale reinvention. Bon Secours appears to be buying a functioning ambulatory engine and preserving the mechanisms that made it competitive.
Eric Evans, chief executive officer of Surgery Partners, called the sale the best path forward for the company and its shareholders. John Starcher Jr., president and chief executive officer of Bon Secours Mercy Health, framed the acquisition as a way to reach more people in more communities across more care settings. The language is broad, but the business logic is precise: outpatient surgery expands access, adds referral flow and gives health systems a way to capture procedures that might otherwise move to independent centers.
Federal policy is widening the case for outpatient surgery
CMS has added 289 procedures to the ASC covered procedures list for 2026 and removed 271 from the inpatient-only list. The policy change widens the clinical and financial territory that can shift into ambulatory settings. In practical terms, more procedures can now be performed safely and reimbursed appropriately outside the hospital inpatient setting, which strengthens the case for systems that own or control a large ASC network.
That policy shift reinforces the commercial appeal of Surgery Partners’ footprint. The company holds interests in more than 200 ASCs, surgical hospitals and physician practices, and it still has room to grow. Nine ASCs are under construction, and more than a dozen are in additional development. For a buyer trying to move quickly, that pipeline is as important as the existing facilities because it extends capacity into new markets without starting from zero.
The commercial logic is even sharper when viewed against recent market activity. Surgery Partners completed the $797 million sale of its interests in two Idaho hospitals to Intermountain Health on Sept. 17, using most of the net proceeds for debt repayment. Earlier in the year, investor Ortelius Advisors pressed the company to sell all of its surgical hospitals. In June, a special committee of independent directors concluded that Surgery Partners would be worth more as an independent public company, yet the subsequent portfolio reshaping and debt reduction created a different financial posture by the time Bon Secours entered the picture.
Regulatory scrutiny will shape the final footprint
The deal still needs shareholder and regulatory approval, and that review will likely focus on market concentration, physician alignment and local competition. Ascension’s experience with Amsurg offers a useful precedent. To clear that transaction, the Federal Trade Commission required the system to divest seven ASCs across five metro areas: Nashville; Panama City, Fla.; Tulsa, Okla.; Waco, Texas; and Wichita, Kan. For 10 years, Ascension must also give the agency 30 days’ notice before acquiring any interest in an ASC in those markets, even when the acquisition would not otherwise trigger a federal filing.
Those conditions show how closely regulators are watching ASC consolidation. Ambulatory centers can increase efficiency and lower costs, but large roll-ups can also reduce competition in local surgical markets if a single system gains too much influence over referrals, scheduling and payer negotiations. Bon Secours Mercy Health’s deal will enter that same review process, and the ultimate footprint may depend on how regulators define competitive overlap in the affected markets.
If completed in the first quarter of 2027, the transaction would give Bon Secours Mercy Health ownership of one of the five largest ASC platforms in the country. Surgery Partners ranked fourth by ASC count at the end of 2025, behind USPI, SCA Health and Amsurg. The deal therefore represents more than a balance-sheet event. It marks another stage in the shift from hospital-centered surgery to a model where control of outpatient capacity is becoming central to system strategy, payer leverage and physician retention.